Survival Benefit of Surgical Resection for Pancreatic Neuroendocrine Tumors With Oligometastatic Liver Metastasis: A Retrospective and Propensity Score-Matching Analysis

Abstract

BackgroundPancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of pancreatic malignancies. Surgical resection is the only curative treatment option for patients with localized PanNETs, yet the role of cancer-directed surgery (CDS) in the setting of oligometastatic liver metastasis remains a controversy.MethodsAll patients diagnosed with PanNETs and liver-only metastasis from 2010 to 2018 were identified from the SEER database. The biases of baseline characteristics between CDS and no-CDS cohorts were reduced by the propensity score-matching (PSM) method, and the prognostic role of CDS was estimated using the Kaplan–Meier method and Cox regression models. Logistic regression analysis was utilized to identify factors associated with patients who underwent CDS.ResultsA total of 1,270 PanNET patients with oligometastatic liver metastasis were included and analyzed. Of these patients, 283 (22.3%) patients underwent CDS of the primary tumor, while the remaining 987 (77.7%) did not. The OS and CSS were significantly better in the CDS cohort regardless of the propensity score analysis. Multivariate analysis revealed that age, tumor differentiation, tumor location, and lymph node status were significantly associated with patients who were more likely to receive CDS.ConclusionOur study demonstrated that CDS was associated with survival benefits in selected patients with PanNETs and liver-only metastasis based on a large population database.

Survival Benefit from Cancer‐Directed Surgery for Metastatic Head and Neck Cancer

“…Unfortunately, only a few studies have demonstrated the potential survival benefit of CDS in patients with M1 HNC, 7,23 and there is a lack of relevant research identifying which patients may benefit most from CDS treatment. In recent years, several studies have supported the survival benefit of CDS in metastatic pancreatic cancer and metastatic breast cancer 24–27 . Although our study was a retrospective analysis, it demonstrated in a large propensity score‐matched patient cohort that CDS offered a survival benefit for M1 HNC.…”

“…In recent years, several studies have supported the survival benefit of CDS in metastatic pancreatic cancer and metastatic breast cancer. [24][25][26][27] Although our study was a retrospective analysis, it demonstrated in a large propensity score-matched patient cohort that CDS offered a survival benefit for M1 HNC. More importantly, the subgroup analysis results can help clinicians to select patients who will most likely benefit from CDS treatment, which may also facilitate recruitment into randomized controlled trials.…”